Rapid expansion in the WAVE bioreactor of clinical scale cells for tumor immunotherapy

References

• Ethun CG, Bilen MA, Jani AB, Maithel SK, Ogan K, Master VA. Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology. CA Cancer J Clin. 2017;67:362–377. doi:10.3322/caac.21406. PMID:28731537.
   PubMed Web of Science ®Google Scholar
• Valent P, Akin C. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129:1420–7. doi:10.1182/blood-2016-09-731893. PMID:28031180.
   PubMed Web of Science ®Google Scholar
• Citrin DE. Recent Developments in Radiotherapy. The N Engl J Med. 2017;377:1065–75. doi:10.1056/NEJMra1608986. PMID:28902591.
   PubMed Web of Science ®Google Scholar
• Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. J Clin Invest. 2015;125:1780–9. doi:10.1172/JCI76094. PMID:25932675.
   PubMed Web of Science ®Google Scholar
• Ward EM, Flowers CR, Gansler T, Omer SB, Bednarczyk RA. The importance of immunization in cancer prevention, treatment, and survivorship. CA Cancer J Clin. 2017;67:398–410. doi:10.3322/caac.21407.
   Web of Science ®Google Scholar
• Reck M. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377:849–61. doi:10.1056/NEJMra1703413. PMID:28854088.
   PubMed Web of Science ®Google Scholar
• Van Limbergen EJ, De Ruysscher DK, Olivo Pimentel V, Marcus D, Berbee M, Hoeben A, Rekers N, Theys J, Yaromina A, Dubois LJ, Lambin P. Combining radiotherapy with immunotherapy: the past, the present and the future. Br J Radiol. 2017;90:20170157. doi:10.1259/bjr.20170157. PMID:28541096.
   PubMed Web of Science ®Google Scholar
• Su Y, Romeu-Bonilla E, Anagnostou A, Fitz-Patrick D, Hearl W, Heiland T. The safety and immunological effects of rAd5-EBV-LMP2 vaccine in nasopharyngeal carcinoma patients: a phase I clinical trial and two-year follow-up. Chem Pharm Bull. 2016;64:1118–23. doi:10.1248/cpb.c16-00114. PMID:27477649.
   PubMed Web of Science ®Google Scholar
• Passalacqua R, Caminiti C, Buti S, Porta C, Camisa R, Braglia L, Tomasello G, Vaglio A, Labianca R, Rondini E. Adjuvant low-dose interleukin-2 (IL-2) plus interferon-alpha (IFN-alpha) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC). J Immunother. 2014;37:440–7. doi:10.1097/CJI.0000000000000055. PMID:25304727.
   PubMed Web of Science ®Google Scholar
• Zhang T, Xie J, Arai S, Wang L, Shi X, Shi N, Ma F, Chen S, Huang L, Yang L, Ma W, Zhang B, Han W, Xia J. The efficacy and safety of anti-PD-1/ PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget. 2016;7:73068–79. PMID:27683031.
   PubMed Web of Science ®Google Scholar
• Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–84. doi:10.1016/S1470-2045(15)70076-8. PMID:25795410.
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroe- sophageal junction. J Clin Oncol. 2016;34:1448–54. doi:10.1200/JCO.2015.63.5995. PMID:26884585.
   PubMed Web of Science ®Google Scholar
• Boye M, Wang X, Srimuninnimit V, Kang JH, Tsai CM, Orlando M, Puri T, Kim JS, Rajan N, Yang JC. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never-smoker patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer: quality of life results from a randomized phase III trial. Clin Lung Cancer. 2016;17:150–60. doi:10.1016/j.cllc.2015.12.004. PMID:26809984.
   PubMed Web of Science ®Google Scholar
• Stanculeanu DL, Daniela Z, Lazescu A, Bunghez R, Anghel R. Development of new immunotherapy treatments in different cancer types. J Med Life. 2016;9:240–8. PMID:27974927.
   PubMedGoogle Scholar
• Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol. 2005;23:7536–45. doi:10.1200/JCO.2005.03.047. PMID:16157940.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor- infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol. 2013;31:2152–9. doi:10.1200/JCO.2012.46.6441. PMID:23650429.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Liao H, Ju Y. Effect of compound Kushen injection on T-cell subgroups and natural killer cells in patients with locally advanced non- small-cell lung cancer treated with concomitant radiochemotherapy. J Tradit Chin Med. 2016;36:14–18. doi:10.1016/S0254-6272(16)30002-4. PMID:26946613.
   PubMed Web of Science ®Google Scholar
• Chia WK, Teo M, Wang WW, Lee B, Ang SF, Tai WM, Chee CL, Ng J, Kan R, Lim WT, Tan SH, Ong WS, Cheung YB. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther. 2014;22:132–9. doi:10.1038/mt.2013.242. PMID:24297049.
   PubMed Web of Science ®Google Scholar
• Jäkel CE, Vogt A, Gonzalez-Carmona MA, Schmidt-Wolf IGH. Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. J Immunol Res. 2014;2014:1–12. doi:10.1155/2014/897214.
   Google Scholar
• Shi L, Zhou Q, Wu J, Ji M, Li G, Jiang J, Wu C. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother. 2012;61:2251–9. doi:10.1007/s00262-012-1289-2. PMID:22674056.
   PubMed Web of Science ®Google Scholar
• Sun C, Dotti G. Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies. Blood. 2016;127:3350–9. doi:10.1182/blood-2015-12-629089. PMID:27207792.
   PubMed Web of Science ®Google Scholar
• Barrett D, Fish JD. Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors. Pediatr Clin North Am. 2010;57:47–66. doi:10.1016/j.pcl.2010.01.001. PMID:20307711.
   PubMed Web of Science ®Google Scholar
• Meng Y, Yu Z, Wu Y, Du T, Chen S, Meng F, Su N, Ma Y, Li X, Sun S, Zhang G. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application. Hum Vaccin Immunother. 2017;13:1–9. doi:10.1080/21645515.2017.1285987.
   Web of Science ®Google Scholar
• Singh V. Method for culturing cells using wave-induced agitation. US Patent. 2001;190:913.
   Google Scholar
• Demanga CG, Eng JWL, Gardiner DL, Roth A, Butterworth A, Adams JH, Trenholme KR, Dalton JP. The development of sexual stage malaria gametocytes in a Wave Bioreactor. Parasit Vectors. 2017;10:216. doi:10.1186/s13071-017-2155-z.
   PubMed Web of Science ®Google Scholar
• Tsai AC, Liu Y, Yuan X, Chella R, Ma T. Aggregation kinetics of human mesenchymal stem cells under wave motion. Biotechnol J. 2016. doi:10.1002/biot. PMID:26849021.
   PubMed Web of Science ®Google Scholar
• Burugu S, Dancsok AR. Emerging targets in cancer immunotherapy. Semin Cancer Biol. 2017; pii: S1044-579X(17)30182-7. doi:10.1016/j.semcancer.2017.10.001. PMID:28987965.
   PubMed Web of Science ®Google Scholar
• Garg AD. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. Immunol Rev. 2017;280:126–48. doi:10.1111/imr.12574. PMID:29027218.
   PubMed Web of Science ®Google Scholar
• Singh N, Shi J, June CH. Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer. Curr Hematol Malig Rep. 2017;12:1–8. doi:10.1007/s11899-017-0417-7. PMID:29039115.
   PubMed Web of Science ®Google Scholar
• Nair S. Natural Killer T Cells in Cancer Immunotherapy. Front Immunol. 2017;8:1178. doi:10.3389/fimmu.2017.01178. PMID:29018445.
   PubMedGoogle Scholar
• López-Soto A, Gonzalez S, Smyth MJ. Control of Metastasis by NK Cells. Cancer Cell. 2017;32:135–54. doi:10.1016/j.ccell.2017.06.009. PMID:28810142.
   PubMed Web of Science ®Google Scholar
• Villadangos JA. Antigen-specific impairment of adoptive T-cell therapy against cancer: players, mechanisms, solutions and a hypothesis. Immunol Rev. 2016;272:169–82. doi:10.1111/imr.12433. PMID:27319350.
   PubMed Web of Science ®Google Scholar
• Keller CW, Freigang S. Reciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential. Front Immunol. 2017;8:570. doi:10.3389/fimmu.2017.00570. PMID:28596767.
   PubMed Web of Science ®Google Scholar
• Dwarshuis NJ, Parratt K, Santiago-Miranda A. Cells as advanced therapeutics: State-of-the-art, challenges, and opportunities in large scale biomanufacturing of high-quality cells for adoptive immunotherapies. Adv Drug Deliv Rev. 2017;114:222–39. doi:10.1016/j.addr.2017.06.005. PMID:28625827.
   PubMed Web of Science ®Google Scholar
• Wong YNS, Joshi K, Pule M, Peggs KS, Swanton C, Quezada SA, Linch M. Evolving adoptive cellular therapies in urological malignancies. Lancet Oncol. 2017;18:e341–53. doi:10.1016/S1470-2045(17)30327-3. PMID:28593860.
   PubMed Web of Science ®Google Scholar
• Scholz J. A re-usable wave bioreactor for protein production in insect cells. MethodsX 2016;3:497–501. doi:10.1016/j.mex.2016.08.001. PMID:27556015.
   PubMed Web of Science ®Google Scholar
• Cirés S, Alvarez-Roa C. First use of the WAVE™ disposable rocking bioreactor for enhanced bioproduct synthesis by N2 -fixing cyanobacteria. Biotechnol Bioeng. 2015;112:621–6. doi:10.1002/bit.25455. PMID:25219374.
   PubMed Web of Science ®Google Scholar
• Lohmueller J. Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther. 2017. doi:10.1016/j.pharmthera.2017.03.008. doi:10.1016/j.pharmthera.2017.03.008.
   PubMed Web of Science ®Google Scholar
• Lim WA. The Principles of Engineering Immune Cells to Treat Cancer. Cell. 2017;168:724–40. doi:10.1016/j.cell.2017.01.016. PMID:28187291.
   PubMed Web of Science ®Google Scholar
• Beatty GL. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. Pharmacol Ther. 2016;166:30–39. doi:10.1016/j.pharmthera.2016.06.010.
   PubMed Web of Science ®Google Scholar
• van der Loo JC, Swaney WP, Grassman E, Terwilliger A, Higashimoto T, Schambach A, Baum C, Thrasher AJ, Williams DA, Nordling DL, et al. Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection. Gene Ther. 2012;19:246–54. doi:10.1038/gt.2011.102. PMID:21753795.
   PubMed Web of Science ®Google Scholar
• Kwon J Y, Yang Y S, Cheon S H, Nam HJ, Jin GH, Kim DI. Bioreactor engineering using disposable technology for enhanced production of hCTLA4Ig in transgenic rice cell cultures. Biotechnol Bioeng. 2013;110:2412–24. doi:10.1002/bit.24916.
   PubMed Web of Science ®Google Scholar
• Dalton J P, Demanga C G, Reiling S J, Wunderlich J, Eng JW, Rohrbach P. Large-scale growth of the Plasmodium falciparum malaria parasite in a wave bioreactor. Int J Parasitol. 2012;42:215–20. doi:10.1016/j.ijpara.2012.01.001. PMID:22326740.
   PubMed Web of Science ®Google Scholar
• Andersson TB. Evolution of Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. Basic Clin Pharmacol Toxicol. 2017;121:234–8. doi:10.1111/bcpt.12804. PMID:28470941.
   PubMed Web of Science ®Google Scholar
• Underhill GH. Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies. Cell Mol Gastroenterol Hepatol. 2018;5:426–39. doi:10.1016/j.jcmgh.2017.11.012. PMID:29675458.
   PubMed Web of Science ®Google Scholar
• Rebelo SP, Pinto C, Martins TR, Harrer N, Estrada MF, Loza-Alvarez P, Cabeçadas J, Alves PM, Gualda E, Sommergruber W, et al. 3D-3-culture: A tool to unveil macrophage plasticity in the tumour microenvironment. Biomaterials 2018;163:185–97. doi:10.1016/j.biomaterials.2018.02.030. PMID:29477032.
   PubMed Web of Science ®Google Scholar
• Prévôt ME, Ustunel S. Liquid Crystal Elastomers-A Path to Biocompatible and Biodegradable 3D-LCE Scaffolds for Tissue Regeneration. Materials (Basel) 2018;11. pii: E377. doi:10.3390/ma11030377.
   PubMed Web of Science ®Google Scholar
• Niehues H, Bouwstra JA, El Ghalbzouri A, Brandner JM, Zeeuwen PLJM, van den Bogaard EH. 3D skin models for 3R research: The potential of 3D reconstructed skin models to study skin barrier function. Exp Dermatol. 2018;27:501–511. doi:10.1111/exd.13531.
   Web of Science ®Google Scholar
• Ho BX, Pek NMQ. Disease Modeling Using 3D Organoids Derived from Human Induced Pluripotent Stem Cells. Int J Mol Sci. 2018;19:pii: E936. doi:10.3390/ijms19040936.
   Web of Science ®Google Scholar
• Costa EC, Moreira AF, de Melo-Diogo D, Gaspar VM, Carvalho MP, Correia IJ. 3D tumor spheroids: an overview on the tools and techniques used for their analysis. Biotechnol Adv. 2016;34:1427–41. doi:10.1016/j.biotechadv.2016.11.002. PMID:27845258.
   PubMed Web of Science ®Google Scholar